ArticleScientific reports2022
National, sub-national, and risk-attributed burden of thyroid cancer in Iran from 1990 to 2019.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- Spatiotemporal Epidemiology of Female Thyroid Cancer: A Retrospective Population-Based Registry Study in the Hamadan Province, Iran (2010-2019).Archives of Iranian medicine · 2025Article
- Advanced machine learning framework for thyroid cancer epidemiology in Iran through integration of environmental socioeconomic and health system predictors.Scientific reports · 2025Article
- Spatial heterogeneity and temporal trends of thyroid cancer incidence in Iran from 2014 to 2017.Scientific reports · 2025Article
- Continued rise in the incidence of thyroid cancer in Iran: true increase or overdiagnosis?Journal of diabetes and metabolic disorders · 2025Article
- Global, regional, and national burden of thyroid cancer in young people aged 10-24 years from 1990 to 2021: an analysis based on the Global Burden of Disease Study 2021.BMC public health · 2025Article
- Burden of thyroid cancer in the older adult aged 60 and over from 1990 to 2021 and forecast of the situation in 2030.Frontiers in oncology · 2025Article
- Article
- Cancer incidence in Iran in 2016: A study based on the Iranian National Cancer Registry.Cancer reports (Hoboken, N.J.) · 2024Review
- Clinicopathological profile and management of thyroid carcinoma: a Sub-Saharan country experience.Thyroid research · 2023Article
- Associations between Lake Urmia disaster and the prevalence of thyroid nodules and metabolic syndrome: The AZAR cohort survey.Health promotion perspectives · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An updated exploration of the burden of thyroid cancer across a country is always required for making correct decisions. The objective of this study is to present the thyroid cancer burden and attributed burden to the high Body Mass Index (BMI) in Iran at national and sub-national levels from 1990 to 2019. The data was obtained from the GBD 2019 study estimates. To explain the pattern of changes in incidence from 1990 to 2019, decomposition analysis was conducted. Besides, the attribution of high BMI in the thyroid cancer DALYs and deaths were obtained. The age-standardized incidence rate of thyroid cancer was 1.57 (95% UI: 1.33-1.86) in 1990 and increased 131% (53-191) until 2019. The age-standardized prevalence rate of thyroid cancer was 30.19 (18.75-34.55) in 2019 which increased 164% (77-246) from 11.44 (9.38-13.85) in 1990. In 2019, the death rate, and Disability-adjusted life years of thyroid cancer was 0.49 (0.36-0.53), and 13.16 (8.93-14.62), respectively. These numbers also increased since 1990. The DALYs and deaths attributable to high BMI was 1.91 (0.95-3.11) and 0.07 (0.04-0.11), respectively. The thyroid cancer burden and high BMI attributed burden has increased from 1990 to 2019 in Iran. This study and similar studies' results can be used for accurate resource allocation for efficient management and all potential risks' modification for thyroid cancer with a cost-conscious view.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.